Chronic Total Occlusion Market Overview, Growth, Trends, Analysis, Research Report (2021-2031)

The chronic total occlusion market size is projected to reach US$ 42.21 billion by 2031 from US$ 24.46 billion in 2024. The market is expected to register a CAGR of 8.2% during 2024–2031. Technological advancements in CTO devices are likely to bring new market trends during the forecast period.

Chronic Total Occlusion Market Analysis

The rising geriatric population is a key driver for the chronic total occlusion (CTO) market. As the world population grows older, cardiovascular diseases become more common. According to the US Census Bureau, the number of Americans aged 65 and above is expected to increase from 58 million in 2022 to 82 million by 2050, which is a 47% increase. The percentage of the population aged 65 and older is expected to increase from 17% to 23% by 2050. According to Statistics Canada, in 2022, around one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age.

Older adults, particularly those over 60 years of age, are at higher risk of cardiovascular diseases due to age-related changes in the cardiovascular system, such as decreased blood vessel elasticity and arterial plaque. The growing elderly population worldwide is driving the need for efficient and minimally invasive treatments, such as percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Older adults often struggle to adjust to traditional surgical methods, which is why there is a rising preference for minimally invasive procedures that promote faster recovery and reduce risk. This is a phenomenon that can be seen in countries with high aging populations, such as the US, Japan, and European nations.

Market players such as Boston Scientific, Abbott Laboratories, and Medtronic are also more inclined to develop sophisticated CTO devices specifically designed for the aging population. These devices make treatments available, effective, and safe for this vulnerable group.

Chronic Total Occlusion Market Overview

The chronic total occlusion market is rapidly expanding due to the increasing aging population and the rising prevalence of cardiovascular diseases. Prominent players operating in the market are focusing on innovation and collaboration for enhanced product availability. However, the high cost of occlusion devices hinders the chronic total occlusion market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Chronic Total Occlusion Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Chronic Total Occlusion Market Drivers and Opportunities

Rising Prevalence of Cardiovascular Diseases

The growing prevalence of cardiovascular diseases (CVDs) such as coronary heart diseases, sudden cardiac arrest, congenital heart diseases, heart failure, pulmonary hypertension, and pulmonary artery pressure (PA) is encouraging cardiovascular interventions. As the number of CVD patients continues to grow, so does the demand for advanced treatments for complex coronary conditions such as CTO. This increasing burden of disease has led to greater adoption of percutaneous coronary intervention (PCI) procedures for treating CTO, particularly in aging populations. According to the World Health Organization (WHO), ~30 million people experience a stroke each year. Moreover, the American Heart Association states more than 130 million people in the US, i.e., 45.1% of the population, are projected to have a type of CVD by 2035.

The European Society of Cardiology reported that atrial fibrillation is the most common arrhythmia, and it accounts for 0.28–2.6% of healthcare spending in European countries. It also mentioned that patients suffering from atrial fibrillation are at a five-time greater risk of getting a stroke, and 20–30% of total stroke cases in Europe are caused due to atrial fibrillation. As per a study conducted by the European Society of Cardiology in 2016, ~7.6 million people aged 65 and above had atrial fibrillation in the EU, and the number is estimated to increase by 89% to reach ~14.4 million by 2060. The prevalence of atrial fibrillation is estimated to reach 9.5% by 2060 from 7.8% in 2016. As per the report “Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific,” by Biosense Webster, published in 2019, more than 16 million people in Asia Pacific suffer from atrial fibrillation, and the number is expected to reach ~72 million by 2050. The report also suggests that the middle-aged and elderly population is at a greater risk of developing this condition.

The WHO estimates 17.9 million lives are lost due to CVDs every year, i.e., 32% of the total deaths reported globally. A few of the primary risk factors of CVDs include family history, ethnicity, and age; other risk factors include tobacco consumption, hypertension, obesity, high cholesterol, physical inactivity, diabetes, unhealthy diets, and alcohol consumption. As CVD incidence continues to rise, the demand for CTO treatments is expected to expand, driving significant growth in the CTO market.

Strategic Initiatives by Market Players

Companies operating in the CTO market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the CTO market are mentioned below.

• In February 2022, Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) granted expanded indications for its specialty catheters and coronary guidewires, specifically for use in chronic total occlusion percutaneous coronary interventions (CTO PCI).
• In June 2024, MicroPort RotaPace’s Intravascular Piezoelectric Guidewire System gained NMPA approval for entry into the special review procedures for innovative medical devices. This system was co-developed by a team led by Academician Junbo Ge from Zhongshan Hospital, Fudan University.
• In February 2024, BIOTRONIK introduced the Micro Rx catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during PCI. The Micro Rx catheter is the fourth IMDS product that BIOTRONIK has introduced to the US market, contributing to a strong portfolio of devices, which includes the NHancer Rx, TrapIT, and ReCross catheters.
• In October 2022, the FDA-approved NovaCross line of microcatheters (NovaCross BTK for below-the-knee treatment, NovaCross Xtreme for chronic total occlusion treatment, and NovaCross CTO for chronic total occlusion treatment) was among the assets that Microbot Medical Inc. purchased from Nitiloop Ltd. The NovaCross devices are designed to make it easier to implant conventional and steerable guidewires intraluminally beyond stenotic lesions, including chronic complete occlusions, prior to percutaneous transluminal coronary angioplasty or stent intervention.
• In April 2022, the FDA approved Transit Scientific's XO Cross Support Catheter Platform for coronary usage. The platform is intended to facilitate wire exchanges, guide and maintain a guidewire during access to the peripheral or coronary arteries, and serve as a conduit for the administration of diagnostic contrast agents or saline solutions.
• In February 2022, the FDA approved an additional indication for Teleflex Incorporated's specialized catheters and coronary guidewires to be used in crossing chronic complete occlusion (CTO) during percutaneous coronary intervention (PCI).
• In September 2023, Avinger, Inc. announced the full commercial launch of its Tigereye ST next-generation image-guided CTO crossing system. With the initiation of a full commercial launch, all current and prospective accounts can now order the Tigereye ST device.

Therefore, product launches, approvals, and collaborations are expected to create ample opportunities for the growth of the chronic complete occlusion (CTO) market in the coming years.

Chronic Total Occlusion Market Report Segmentation Analysis

Key segments that contributed to the derivation of the chronic total occlusion market analysis are equipment and end user.

• Based on equipment, the chronic total occlusion market is segmented into guide wires, micro catheters, crossing devices, re-entry devices, and others. The guide wires segment held the largest share of the market in 2024.
• In terms of end user, the chronic total occlusion market is categorized into hospitals, ambulatory care centers, and others. The hospitals segment dominated the market in 2024.

Chronic Total Occlusion Market Share Analysis by Geography

The geographic scope of the chronic total occlusion market report mainly focuses on five regions: North America, Asia Pacific, Europe, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the market in 2024. It is expected to continue its dominance in the global market during the forecast period. The US is the largest market for chronic total occlusion in the world. The US chronic total occlusion market is growing with the rising incidence of CVD, especially Coronary Artery Disease (CAD), in the aging population. The American Heart Association’s (AHA) 2023 Heart Disease and Stroke Statistics Update mentions that approximately 18.2 million adults in the country had CAD. The adoption of minimally invasive methods, including percutaneous coronary intervention (PCI), and the development of sophisticated CTO-specific devices are the major driving forces for market growth. Global leaders such as Medtronic, Boston Scientific, Abbott Laboratories, and Philips Healthcare dominate the US market with their innovative devices and technologies for CTO procedures. The strong healthcare infrastructure, reimbursement policies, and emphasis on enhancing patient outcomes fuel market growth. The growing number of specialized centers and well-trained cardiologists favor the application of CTO procedures. As per the Division of Occupational Employment and Wage Statistics, there were 15,190 employed cardiologists in the US as of 2023. In addition, growing consciousness about cardiovascular health and detection of CTO at an early stage fuel the demand for these interventions.

Chronic Total Occlusion Market Regional Insights

The regional trends and factors influencing the Chronic Total Occlusion Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Chronic Total Occlusion Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Chronic Total Occlusion Market Report Scope

Chronic Total Occlusion Market Players Density: Understanding Its Impact on Business Dynamics

The Chronic Total Occlusion Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Chronic Total Occlusion Market are:

1. Asahi Intecc Co Ltd
2. Cordis Corp
3. Integer Holdings Corp
4. Boston Scientific Corp
5. Becton Dickinson and Co
6. SoundBite Medical Solutions

Disclaimer: The companies listed above are not ranked in any particular order.

Chronic Total Occlusion Market News and Recent Developments

The chronic total occlusion market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Below are a few of the key developments witnessed in the chronic total occlusion market:

• Asahi Intecc Co., Ltd. announced that it has signed an agreement to establish a joint venture company with ELDORET HOSPITAL LTD to operate a new hospital specializing in cardiovascular diagnostics and treatments. (Source: Asahi Intecc Co., Ltd., Press Release,  October 2023)
• BD (Becton, Dickinson and Company) announced the launch and 510(k) clearance from the FDA of the Crosser iQ CTO recanalization system, which is designed to cross peripheral artery chronic total occlusions (CTOs) intraluminally. (Source: BD, Press Release, January 2022)

Chronic Total Occlusion Market Report Coverage and Deliverables

The "Chronic Total Occlusion Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Chronic total occlusion market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Chronic total occlusion market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Chronic total occlusion market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the chronic total occlusion market
• Detailed company profiles